81 related articles for article (PubMed ID: 21612575)
1. Drug combinations enhancing the antineoplastic effects of erlotinib in high-grade glioma.
Karpel-Massler G; Wirtz CR; Halatsch ME
Recent Pat Anticancer Drug Discov; 2011 Sep; 6(3):384-94. PubMed ID: 21612575
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours.
Halatsch ME; Schmidt U; Behnke-Mursch J; Unterberg A; Wirtz CR
Cancer Treat Rev; 2006 Apr; 32(2):74-89. PubMed ID: 16488082
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic inhibition of the epidermal growth factor receptor in high-grade gliomas: where do we stand?
Karpel-Massler G; Schmidt U; Unterberg A; Halatsch ME
Mol Cancer Res; 2009 Jul; 7(7):1000-12. PubMed ID: 19584260
[TBL] [Abstract][Full Text] [Related]
4. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
5. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
[TBL] [Abstract][Full Text] [Related]
6. Molecular study of malignant gliomas treated with epidermal growth factor receptor inhibitors: tissue analysis from North American Brain Tumor Consortium Trials 01-03 and 00-01.
Lassman AB; Rossi MR; Raizer JJ; Abrey LE; Lieberman FS; Grefe CN; Lamborn K; Pao W; Shih AH; Kuhn JG; Wilson R; Nowak NJ; Cowell JK; DeAngelis LM; Wen P; Gilbert MR; Chang S; Yung WA; Prados M; Holland EC
Clin Cancer Res; 2005 Nov; 11(21):7841-50. PubMed ID: 16278407
[TBL] [Abstract][Full Text] [Related]
7. Resistance to small molecule inhibitors of epidermal growth factor receptor in malignant gliomas.
Li B; Chang CM; Yuan M; McKenna WG; Shu HK
Cancer Res; 2003 Nov; 63(21):7443-50. PubMed ID: 14612544
[TBL] [Abstract][Full Text] [Related]
8. Treatment schedule is of importance when gefitinib is combined with irradiation of glioma and endothelial cells in vitro.
Andersson U; Johansson D; Behnam-Motlagh P; Johansson M; Malmer B
Acta Oncol; 2007; 46(7):951-60. PubMed ID: 17917826
[TBL] [Abstract][Full Text] [Related]
9. Cooperative inhibitory effect of ZD1839 (Iressa) in combination with 17-AAG on glioma cell growth.
Premkumar DR; Arnold B; Pollack IF
Mol Carcinog; 2006 May; 45(5):288-301. PubMed ID: 16550610
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
11. New treatment strategies for malignant gliomas.
Sathornsumetee S; Rich JN
Expert Rev Anticancer Ther; 2006 Jul; 6(7):1087-104. PubMed ID: 16831080
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic targeting of EGFR in malignant gliomas.
Ye F; Gao Q; Cai MJ
Expert Opin Ther Targets; 2010 Mar; 14(3):303-16. PubMed ID: 20148717
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; Kulesza P; Sebastiani V; Maitra A; Hidalgo M
Cancer Res; 2005 Apr; 65(8):3003-10. PubMed ID: 15833824
[TBL] [Abstract][Full Text] [Related]
14. Interstitial infusion of erlotinib in the rodent brain.
Luther N; Karampelas I; Souliopoulos EP; Edgar MA; Boockvar JA; Souweidane MM
J Exp Ther Oncol; 2009; 8(2):79-84. PubMed ID: 20192114
[TBL] [Abstract][Full Text] [Related]
15. Everolimus synergizes with gefitinib in non-small-cell lung cancer cell lines resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Dong S; Zhang XC; Cheng H; Zhu JQ; Chen ZH; Zhang YF; Xie Z; Wu YL
Cancer Chemother Pharmacol; 2012 Nov; 70(5):707-16. PubMed ID: 22941374
[TBL] [Abstract][Full Text] [Related]
16. A feasibility and efficacy study of rapamycin and erlotinib for recurrent pediatric low-grade glioma (LGG).
Yalon M; Rood B; MacDonald TJ; McCowage G; Kane R; Constantini S; Packer RJ
Pediatr Blood Cancer; 2013 Jan; 60(1):71-6. PubMed ID: 22434731
[TBL] [Abstract][Full Text] [Related]
17. Antitumor efficacy of cytotoxic drugs and the monoclonal antibody 806 is enhanced by the EGF receptor inhibitor AG1478.
Johns TG; Luwor RB; Murone C; Walker F; Weinstock J; Vitali AA; Perera RM; Jungbluth AA; Stockert E; Old LJ; Nice EC; Burgess AW; Scott AM
Proc Natl Acad Sci U S A; 2003 Dec; 100(26):15871-6. PubMed ID: 14676326
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib (OSI-774)-induced inhibition of transitional cell carcinoma of bladder cell line growth is enhanced by interferon-alpha.
Yang JL; Qu XJ; Hayes VM; Brenner PC; Russell PJ; Goldstein D
BJU Int; 2007 Jun; 99(6):1539-45. PubMed ID: 17346275
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
Norden AD; Young GS; Setayesh K; Muzikansky A; Klufas R; Ross GL; Ciampa AS; Ebbeling LG; Levy B; Drappatz J; Kesari S; Wen PY
Neurology; 2008 Mar; 70(10):779-87. PubMed ID: 18316689
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Reardon DA; Wen PY
Oncologist; 2006 Feb; 11(2):152-64. PubMed ID: 16476836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
